Tuberculosis, or TB, is a contagious bacterial infection that primarily affects the lungs. While curative treatments exist, more than 80% of cases occur in low- and middle-income nations, where drug-resistant strains are on the rise and the cost of medications is a burden. A new class of antibiotics has shown promise against multidrug- and extensively drug-resistant TB, but its manufacturing cost is a barrier to access in poorer countries that need the treatments most.